임상 레이더 AI

TG 테라퓨틱스이(가) 주요 의뢰자 또는 협력자로 참여한 임상시험을 함께 살펴보고 논의해 봅시다.

건강 상태와 치료법을 이해하고 근처 임상 시험을 찾는 데 도움을 드릴 수 있어요.
저희 검색 도구는 영어만 지원합니다. 다른 언어로 검색하고 싶으시면 상단의 임상 레이더 AI를 사용하거나 아래 질환명 및 위치 필터를 선택하세요.
32 임상시험
 
키워드
Ublituximab
×
 
임상시험 제목
상태
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis NCT07389590
대상자모집전
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis NCT07225361
모집중
Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis NCT07220252
대상자모집전
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS) NCT07211633
모집중
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis NCT06864936
대상자모집전
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) (ENABLE) NCT06433752
모집중
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab (ENHANCE) NCT05877963
모집중
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia NCT04806035
조기 종료
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL NCT04624633
진행중, 모집종료결과 게시됨
Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy NCT04149821
조기 종료결과 게시됨
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis NCT04130997
진행중, 모집종료
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax NCT04016805
조기 종료결과 게시됨
Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma NCT03828448
조기 종료결과 게시됨
Study of TG-1801 in Subjects With B-Cell Lymphoma NCT03804996
완료
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) NCT03801525
조기 종료결과 게시됨
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma NCT03778073
조기 종료
Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies NCT03671590
조기 종료
An Extension of the TG1101-RMS201 Trial NCT03381170
완료
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL NCT03379051
조기 종료
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) NCT03277261
완료결과 게시됨
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (ULTIMATE II) NCT03277248
완료결과 게시됨
Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials NCT03207256
조기 종료
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL) NCT02793583
조기 종료
Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis NCT02738775
완료결과 게시됨
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 NCT02656303
조기 종료결과 게시됨
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (UNITY-CLL) NCT02612311
조기 종료결과 게시됨
Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation NCT02535286
완료
Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (GENUINE) NCT02301156
완료결과 게시됨
Ublituximab + Ibrutinib in Select B-cell Malignancies NCT02013128
완료
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies NCT02006485
완료
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies NCT01744912
조기 종료
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma NCT01647971
완료